Nuvation Bio's core business segment revolves around the research, development, and clinical advancement of novel oncology therapeutics. This includes a diverse pipeline of small molecule inhibitors, such as NUV-422 targeting CDK2/4/6, NUV-868 as a BET inhibitor, and NUV-569 inhibiting Wee1 kinase. The company also focuses on drug-drug conjugate (DDC) platforms to enhance the efficacy of existing anti-cancer drugs. Research and development activities are geared towards identifying and validating new drug targets, conducting preclinical studies, and executing clinical trials to assess safety and efficacy. The therapeutic areas of focus include lung cancer, breast cancer, and ovarian cancer, with the aim of providing meaningful improvements in patient outcomes and survival. Nuvation Bio leverages its expertise in medicinal chemistry, molecular biology, and clinical development to create differentiated therapies with the potential to address unmet medical needs in oncology.